Life sciences & biotechnology
Protecting IP in plant-based ‘meat-substitutes’
Innovation in the plant-based meat sector is aiming to help to solve some of the problems associated with animal-meat production.
Careful planning – Cell and gene therapy IP strategy
Claire Devine and Barbara Fleck discuss the importance of early planning in cell and gene therapy IP strategy.
Protecting IP in lab-grown organs – organoids
Lab-grown miniature organs (also known as organoids) is a technology area that has the potential to significantly lower costs and failure rates in drug development, and to improve safety.
Who are the players in the digital healthcare space for medicine development? An analysis of patent filing trends
In this article, we look at some of the recent patenting trends and challenges in the digital healthcare space, with a spotlight on digital healthcare for medicine development.
G02/21 Plausibility
A new EPO referral to the enlarged BoA will determine whether post-filed data can be used to support inventive step and plausibility.
How much data is needed for biotech applications at the EPO?
Claire Devine explains the need for a robust patent filing and prosecution strategy that mitigates against objections for lack of plausibility at the EPO.
